clinical trial · NCT06668493
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Low-grade Upper Tract Urothelial CarcinomaNadofaragene Firadenovec
brief summary
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.
started
Jun 12, 2025
primary completion
Nov 30, 2029
completion
Nov 30, 2029
last updated
Feb 27, 2026
official title
A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects With Low-grade Upper Tract Urothelial Carcinoma (LG-UTUC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol